scholarly journals Image Guidance-Assisted Decompression and Removal of Heterotopic Ossification Following the Use of Recombinant Human Bone Morphogenetic Protein-2 in Transforaminal Lumbar Interbody Fusion

Cureus ◽  
2021 ◽  
Author(s):  
Julie L Chan ◽  
Robert A Ravinsky ◽  
J Patrick Johnson ◽  
Eli M Baron
Keyword(s):  
Heterotopic Ossification ◽  
Bone Morphogenetic Protein ◽  
Image Guidance ◽  
Interbody Fusion ◽  
Transforaminal Lumbar Interbody Fusion ◽  
Bone Morphogenetic Protein 2 ◽  
Lumbar Interbody Fusion ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

scholarly journals Evaluation of Heterotopic Ossification After Using Recombinant Human Bone Morphogenetic Protein–2 in Transforaminal Lumbar Interbody Fusion: A Computed Tomography Review of 996 Disc Levels

2019 ◽  
Vol 10 (3) ◽  
pp. 280-285
Author(s):  
Shuo Niu ◽  
Albert T. Anastasio ◽  
Razan R. Faraj ◽  
John M. Rhee
Keyword(s):  
Computed Tomography ◽  
Heterotopic Ossification ◽  
Interbody Fusion ◽  
Transforaminal Lumbar Interbody Fusion ◽  
Bone Morphogenetic Protein 2 ◽  
Control Group ◽  
Lumbar Interbody Fusion ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

Study Design: Retrospective cohort study. Objectives: Reported incidences and complications of heterotopic ossification (HO) after using recombinant human bone morphogenetic protein–2 (rhBMP-2) in transforaminal lumbar interbody fusion (TLIF) have been inconclusive. This study was designed to evaluate both incidences of radiologic and symptomatic HO in a large series of TLIFs using rhBMP-2. Methods: A total of 996 disc levels in 927 consecutive TLIF patients were retrospectively evaluated at 6-month postoperative follow-up in a single surgical practice. Subjects were separated into the BMP group and the control group. Operative reports, pre- and postoperative medical records were reviewed. Computed tomography (CT) scans were analyzed and graded independently for ossification at each disc level of TLIF. Results: A total of 933 disc levels were in the BMP group, and 63 were in the control group. Six-month fusion rate of interbody was 92.5% in the BMP group, which was significantly higher in contrast to 71.4% in the control group ( P < .001). The incidence of radiologic HO in the BMP group was 13.5%, which was significantly higher than 1.6% in the control group ( P = .006). After controlling for basic demographics and comorbidities, the presence of radiologic HO was significantly associated with the use of rhBMP-2 ( P = .026). However, only one case in the BMP group (0.11%) developed a symptomatic HO (mild-medium left buttock pain, treated nonsurgically) involving left foramen of L5-S1. Conclusions: rhBMP-2 can be safely used in TLIF with regard to HO. There was a low rate of radiologic HO and minimal symptomatic HO, with high fusion rates at 6 months postoperative.

scholarly journals Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein–2 added to 70:30 poly(L-lactide-co-D,L-lactide) bioresorbable implants

2004 ◽  
Vol 16 (3) ◽  
pp. 1-4 ◽  
Author(s):  
Todd H. Lanman ◽  
Thomas J. Hopkins
Keyword(s):  
Bone Graft ◽  
Bone Morphogenetic Protein ◽  
Interbody Fusion ◽  
Human Bone ◽  
Bone Morphogenetic Protein 2 ◽  
Ct Scans ◽  
Lumbar Interbody Fusion ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

Object To evaluate the effectiveness of recombinant human bone morphogenetic protein–2 (rhBMP-2) combined with a bioresorbable implant, the authors conducted a prospective study of 43 patients with degenerative lumbar disc disease who underwent transforaminal lumbar interbody fusion. Methods The authors used Infuse bone graft, which consisted of rhBMP-2 applied to an absorbable collagen sponge and contained within a HYDROSORB Telamon bioresorbable implant to perform the fusion. Multilevel fusions were performed in 30% of the 43 patients, for a total of 57 levels. At 6 months postoperatively, x-ray films and computerized tomography (CT) scans demonstrated solid fusion in 98% of 41 patients. Improvement from the baseline Oswestry Disability Rating was demonstrated at 6 months postoperatively in 68% of the patients, based on the Oswestry Disability Questionnaire. At 12 months all 11 patients in whom CT scans were obtained showed complete bridging of bone; there were no device-related complications. Conclusions Results in this series provide evidence of the feasibility of using HYDROSORB Telamon biore-sorbable spacers in combination with Infuse bone graft for lumbar spine fusion.

scholarly journals Fusion Rates of Lateral Lumbar Interbody Fusion Using Recombinant Human Bone Morphogenetic Protein-2

2018 ◽  
Vol 9 (4) ◽  
pp. 398-402 ◽  
Author(s):  
Ardalan A. Nourian ◽  
Justin Harrington ◽  
Pamela A. Pulido ◽  
Julie C. McCauley ◽  
James D. Bruffey ◽  
...  
Keyword(s):  
Bone Morphogenetic Protein ◽  
Interbody Fusion ◽  
Human Bone ◽  
Bone Morphogenetic Protein 2 ◽  
Complete Fusion ◽  
Lumbar Interbody Fusion ◽  
Lateral Lumbar Interbody Fusion ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

Study Design: Retrospective observational case series. Objectives: Lateral lumbar interbody fusion (LLIF) has been widely performed with recombinant human bone morphogenetic protein-2 (rhBMP-2), but the fusion rates using this graft alternative have not been well studied. We aimed to evaluate fusion rates in 1- and 2-level LLIF with rhBMP-2 and their relationship with fixation, as well as rates of BMP-related complications. Methods: Institutional review board (IRB)–approved spine registry cohort of 93 patients who underwent LLIF with rhBMP-2 (71 one-level cases and 22 two-level cases). Minimum 1-year clinical follow-up and computed tomography (CT) scan for fusion assessment. Postoperative CT scans were used to evaluate the rate of fusion in all patients. Instrumentation and complications were collected from chart and imaging review. Results: Average age was 65 years (67% female). For 1-level cases, 92% (65/71) had complete fusion and 8% (6/71) had either incomplete or indeterminate fusion. Three of the 6 patients who had incomplete or indeterminate fusion had bilateral pedicle screw instrumentation, 1 patient had unilateral posterior fixation, and 2 had no fixation. In 2-level cases, 86% (19/22) had complete fusion and 14% (3/22) had either incomplete or indeterminate fusion. The 3 patients who had incomplete or indeterminate fusion did not have fixation. Conclusion: Interbody fusion rates with rhBMP-2 via LLIF was 92% in 1-level cases and 86% in 2-level cases, indicating that rhBMP-2 may be used as a viable graft alternative to allograft options for LLIF. Higher rates of pseudarthrosis occurred when not using fixation.

Sign in / Sign up

Export Citation Format

Share Document